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Summary
T cells play a key role in the pathogenesis of type 1 diabetes, and target-
ing the CD3 component of the T-cell receptor complex provides one ther-
apeutic approach. Anti-CD3 treatment can reverse overt disease in
spontaneously diabetic non-obese diabetic mice, an effect proposed to, at
least in part, be caused by a selective depletion of pathogenic cells. We
have used a transfer model to further investigate the effects of anti-CD3
treatment on green fluorescent protein (GFP)+ islet-specific effector T
cells in vivo. The GFP expression allowed us to isolate the known effectors
at different time-points during treatment to assess cell presence in various
organs as well as gene expression and cytokine production. We find, in
this model, that anti-CD3 treatment does not preferentially deplete the
transferred effector cells, but instead inhibits their metabolic function and
their production of interferon-c. Programmed cell death protein 1 (PD-1)
expression was up-regulated on the effector cells from anti-CD3-treated
mice, and diabetes induced through anti-PD-L1 antibody could only be
reversed with anti-CD3 antibody if the anti-CD3 treatment lasted beyond
the point when the anti-PD-L1 antibody was washed out of the system.
This suggests that PD-1/PD-L1 interaction plays an important role in the
anti-CD3 antibody mediated protection. Our data demonstrate an addi-
tional mechanism by which anti-CD3 therapy can reverse diabetogenesis.
Keywords: diabetes; transgenic/knockout mouse; tolerance/suppression/
anergy; antibodies.
Introduction
Anti-CD3 treatment was identified over 20 years ago as a
promising candidate for treatment of type 1 diabetes,
when Chatenoud et al. showed that injection of an anti-
CD3 antibody could reverse disease in overtly diabetic
non-obese diabetic (NOD) mice.1 Since then, clinical tri-
als have attempted to achieve the same results using non-
activating humanized monoclonal anti-CD3 such as tepli-
zumab2,3 and otelixizumab.4,5 Although some have
reported prolonged periods of endogenous insulin pro-
duction and lower insulin injection dose requirements,5–7
these trials have not succeeded in reversing diabetes long
term.8 Continued study of all possible tolerogenic mecha-
nisms that can be harnessed by anti-CD3 therapy is
essential for establishing how this treatment could be
used to its full potential. Treatment with anti-CD3 results
in reversal of established diabetes in NOD mice1 through
a combination of early and long-lasting mechanisms.
CD3-specific antibodies can induce anergy in T cells
through incomplete activation providing signalling
through the T-cell receptor (TCR) complex without
accompanying co-stimulation,9,10 and can also induce T-
cell apoptosis.9,10 Although anti-CD3 treatment reduces
Abbreviations: BMDC, bone-marrow-derived dendritic cell; GFP, green fluorescent protein; GSEA, gene set enrichment analysis
(; HbA1c, glycosylated haemoglobin; IFN-c, interferon-c; IL-2, interleukin-2; NOD, non-obese diabetic; PD-1, programmed cell
death protein 1; PI3K, phosphoinositide 3-kinase; TCR, T-cell receptor; TGF, transforming growth factor ; Th1, T helper 1 sub-
set; Treg, regulatory T
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T-cell numbers, the regulatory Foxp3+ T-cell (Treg cell)
compartment remains undiminished, leading to an
increase in the proportion of Treg cells present in blood
and secondary lymphoid tissues.11,12 A compelling sugges-
tion is that anti-CD3 treatment primarily depletes acti-
vated T cells,13 which has been supported by studies
using ovalbumin-specific cells.11,14
In this study, we have used green fluorescent protein
(GFP)-labelled T helper type 1 (Th1) differentiated islet-
specific effector cells15,16 to study in detail the effects of
anti-CD3 treatment on effector T cells with an Fc-
mutated (aglycosylated) mouse equivalent of otelix-
izumab. We observed, in this model, that anti-CD3 treat-
ment did not preferentially deplete these cells, but rather
suppressed their capacity to produce interferon-c (IFN-c)
in response to stimulation and increased their cell surface
expression of programmed cell death protein 1 (PD-1).
Gene set analysis of microarray data demonstrated funda-
mental changes in the anti-CD3-treated isolated effector
cells compared with control antibody-treated, indicating
the down-regulation of genes associated with glycolysis,
activation and co-stimulation. This finding offers a fur-
ther mechanism to explain the therapeutic benefits of
anti-CD3 treatment in establishing a tolerogenic milieu.
Materials and methods
Mice and diabetes detection
Female NOD mice, NOD-scid mice, BDC2.5 NOD
mice15, NOD-CD2-GFP mice,17 BDC25 9 NOD-CD2-
GFP F1 mice and NOD-Foxp3-GFP mice
18 were bred in
the Department of Pathology, University of Cambridge
and maintained under specific pathogen-free conditions.
The mice are housed in individually ventilated cages with
free access to standard chow and water. Diabetes was
detected using Diastix reagent strips (Bayer Diagnostics,
Basingstoke, UK) and confirmed by a blood glucose mea-
surement of > 133 mM, using a Breeze2 blood glucose
meter (Bayer). This study was carried out in strict accor-
dance with UK Home Office project licence regulations
(Project Licence number 80/2442 and 70/8442) after
approval by the Ethical Review Committee of the Univer-
sity of Cambridge.
Antibody treatment
Aglycosyl anti-CD3 antibody. The non-Fc receptor-bind-
ing anti-mouse CD3 antibody (agly-anti-CD3) was gener-
ated through genetic engineering in the Waldmann
Laboratory, University of Oxford. It consists of the anti-
gen-binding variable domain of the anti-mouse CD3 KT3
clone fused to mutated (non-FcR binding) human IgG1
heavy and j light chains. Chimeric KT3-1.1 aglycosyl
IgG1 antibody mRNA was prepared from the cells of the
hybridoma KT3-1.1 and cDNA was prepared by anchor-
tailed PCR. Splicing by overlap extension PCR was then
carried out for the light chain using primers (1) MR1KT3
50-
TGTGACCCTGCTGCTCTGGGTGTCTGGTGCCTGTG-
CAGACATCCAGATGACCCAGTCTCC and (2) KT3VL-
CK 30-TGCAGCCACAGTCCGTCTCAATTCCACCTTGG
TGCCTCC for VL and primers (3) KT3VL-CK 50-GAAT
TGAGACGGACTGTGGCTGCACCATCTGTCTTCATC
and (4) huCKH111 30-TGAGCCAAGCTTTCAACACTCT
CCCCTGTTGAAGCTCTT for Ck. Primers 1 and 4 were
then used to assemble light-chain constructs. Splicing by
overlap extension PCR was also carried out for the heavy
chain using primers (5) KT3VhH111 50-TCTAG-
TAAGCTTGCCGCCACCATGGACTTCAGGCTCAGCCT
GGCTTTC and (6) KT3CH1 30-TTGCTGGAGGCTGAG-
GAGACTGCGACCATGACTCCTTGG for VH and pri-
mers (7) KT3CH1 50-CGCAGTCTCCTCAGCCTCCACCA
AGGGCCCATCGGTCTT and (8) huCH3ER1 30-
TAGATCGAATTCGGGGCCGTCGCACTCATTTACCCG-
GAGACAGGG for constant region. Primers 5 and 8 were
then used to assembly a heavy-chain aglycosyl IgG1 con-
struct. The amplified light-chain fragment was cloned
into the HindIII site of PEE12 vector (Lonza, Basel,
Switzerland) and the heavy chain was cloned into the
HindIII and EcoRI sites of PEE12. The resulting plasmids
were co-transfected by electroporation into the cell line
NSO and stable transfectants were selected in glutamine-
free Iscove’s modified Dulbecco’s medium (Invitrogen,
Carlsbad, CA). Positive clones were selected by ELISA for
binding to anti-human IgG1 and by FACS for binding to
EL4 cells. Antibody was purified by Protein A (GE
Healthcare, Chalfont St Giles, UK) and tested for endo-
toxin. The antibody that recognizes human CD3 (otelix-
izumab) was used as a non-binding isotype control.
Anti-PD-L1 antibody. Anti-mouse programmed cell
death ligand 1 (PD-L1) antibody (clone MIH5, grown in-
house) was administered intraperitoneally once at a dose
of 2 mg.
Th1 differentiation for in vitro studies and adoptive
transfer
CD4+ CD62Lhi CD25 B220 T cells were isolated by cell
sorter (MoFlo; Beckman Coulter, Brea, CA) from 5-week-
old BDC2.5 TCR transgenic NOD mice and differentiated
into Th1 cells by culturing them in Iscove’s modified
Dulbecco’s medium (Gibco, Grand Island, NY) supple-
mented with 10% fetal calf serum, 50 lM b-mercap-
toethanol, L-glutamine (2 mM) and 50 U/ml penicillin
and streptomycin (Gibco) with plate-bound anti-CD3
(2 lg/ml, clone 145-2C11, grown in-house), soluble anti-
CD28 (10 lg/ml; BD Pharmingen, Franklin Lakes, NJ)
and interleukin-2 (IL-2; 100 U/ml), IL-12 (10 ng/ml) and
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interferon-c (IFN-c; 100 U/ml) (all from Peprotech,
Rocky Hill, NJ) for 4 days at 37° with 5% CO2. After-
wards, the production of IFN-c was checked by specific
ELISA (R&D Systems, Minneapolis, MN) and/or intracel-
lular staining.
Proliferation studies
For determination of in vivo proliferation, BDC2.5 CD4+
T cells were stained with CFSE (5 lM) and injected intra-
venously into 6-week-old NOD mice that had received a
Th1 cell transfer 1 week previously and subsequent treat-
ment with agly-anti-CD3 or control antibody for 4 days.
Seventy-two hours after injection of the CFSE-labelled
cells the indicated lymph nodes were harvested and the
cells were stained for surface markers. For determination
of in vitro proliferation, BDC2.5 CD4+ T cells were
stained with CFSE (5 lM) and co-cultured for 72 hr with
whole pancreatic lymph nodes from 6-week-old NOD
mice, which had received a Th1 cell transfer 1 week pre-
viously and had subsequently received treatment with
agly-anti-CD3 or control antibody for 4 days.
Co-culture with bone-marrow-derived dendritic cells
Bone marrow was harvested from the femurs of NOD
mice and cultured in 50 ml Dulbecco’s modified Eagle’s
medium supplemented as above plus 10 ng/ml granulo-
cyte–macrophage colony-stimulating factor (Peprotech)
for 10 days. For co-culture the cells were pulsed with
BDC2.5 mimotope RTRPLWVRME (1 µg/ml; Cambridge
Peptides, Birmingham, UK) or not. For co-culture, the
BDC2.5 Th1 differentiated cells were pre-incubated with
the indicated concentration of agly-anti-CD3 or control
antibody for 1 hr at 4° and then washed. Bone-marrow-
derived dendritic cells (BMDC; 25 9 105 cells per well)
and Th1 cells (5 9 105 cells per well) were then co-cul-
tured in 24-well plates for 48 hr, after which supernatants
were collected for cytokine analysis and cells were col-
lected for analysis of CD80 expression.
Supernatant cytokine analysis
Cytokine levels in cell culture supernatants were detected
using a cytometric bead array (eBioscience, San Diego,
CA) according to the manufacturer’s instructions. The
R&D Systems ELISA kit for detection of IL-12 (p40) was
used according to the manufacturer’s instructions.
Antibodies and flow cytometry
Cell suspensions from lymph nodes and spleen were pre-
pared by dispersion between glass slides. Intestine and
pancreas were manually dispersed, and then further
digested with collagenase solution (05 mg/ml; Sigma, St
Louis, MO) as previously described.19 All cell prepara-
tions were resuspended in FACS buffer (PBS with 05%
BSA) and incubated with Fc-block (eBioscience). Cell
death was assessed with 7AAD (BD Bioscience, Franklin
Lakes, NJ). Foxp3 was detected using intracellular cyto-
kine staining kit and anti-Foxp3 from eBioscience. Data
were collected on a Cyan Cell Cytometer (DAKO, Santa
Clara, CA) and analysed using FLOWJO (Tree Star Inc.,
Ashland, OR). For intracellular cytokine staining, the cells
were stimulated with PMA (50 ng/ml) and ionomycin
(2000 ng/ml) for 5 hr. Brefeldin A (5 lg/ml) was added
for the last 3 hr and stained with allophycocyanin-conju-
gated anti–IFN-c (XMG1.2) or allophycocyanin-conju-
gated IgG1 isotype controls (BD Pharmingen).
Mitotracker and mitosox assays (both from Thermo
Fisher, Waltham, MA) were performed according to the
manufacturer’s instructions, with incubation for 30 min
at 37° (mitotracker) or 10 min at 37° (mitosox).
Immunofluorescence
Pancreata were fixed in 4% paraformaldehyde for 72 hr,
dehydrated in sucrose and mounted in OCT. Ten-micron
sections were cut on a Leica cryostat onto Polysine slides
(VWR), air-dried and fixed again for 10 min in acetone.
Guinea-pig-anti-insulin antibody (DAKO) was detected
with anti-guinea-pig Alexa 546 (Molecular Probes,
Eugene, OR). Anti-CD4 (BD) was detected with anti-rat
Alexa 488 (Molecular Probes). GLUT-1 in cells was
detected using ab15309 (Abcam, Cambridge, UK) and
Alexa 647 anti-rabbit (Molecular Probes) after permeabi-
lization with PBS-Triton-X. Nuclei were visualized with
DAPI (Molecular Probes). The sections were viewed with
a confocal microscope (Zeiss, Oberkochen, Germany) and
processed using ZEN software.
Microarray
RNA was assessed for concentration and quality using a
SpectroStar (BMG Labtech, Aylesbury, UK) and a Bio-
analyser (Agilent Technologies, Cheadle, UK). Microarray
experiments were performed at Cambridge Genomic Ser-
vices, University of Cambridge, using the MouseWG-6
v2 Expression BeadChip (Illumina, Chesterford, UK)
according to the manufacturer’s instructions. Briefly,
total RNA was amplified using the Ovation Pico WTA
v2 kit (NuGEN Technologies, Leek, Netherlands) and
subsequently labelled using the BiotinIL kit (NuGEN
Technologies) following the manufacturer’s instructions.
The concentration, purity and integrity of the resulting
cRNA were measured using the Nanodrop ND-1000
(Thermo Scientific, Paisley, UK) and by BIOANALYSER.
Finally, cRNA was hybridized to the MouseWG-6 v2
BeadChip and scanned using the Bead Array Reader
(Illumina).
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Raw data were loaded into R using the LUMI package
from bioconductor20 (http://bioconductor.org) and
divided into subsets according to the groups being com-
pared; only the samples involved in a given comparison
are used. Subsets were then filtered to remove any non-
expressed probes using the detection P-value from Illu-
mina. Across all samples, probes for which the intensity
values were not statistically significantly different
(P > 001) from the negative controls were removed from
the analysis. The data were transformed using the Vari-
ance Stabilization Transformation (VST21) from LUMI and
then normalized to remove technical variation between
arrays using quantile normalization. Comparisons were
performed using the LIMMA package22 with results cor-
rected for multiple testing using a False Discovery Rate
(FDR) correction. Finally, the quality of the data was
assessed along with the correlations between samples
within groups.
Gene set enrichment analysis (GSEA) was performed as
previously described.23 Molecular signatures (http://
www.broad.mit.edu/gsea) interrogated included Hallmark
(H), curated (C2) and gene ontology (C5) groups includ-
ing KEGG, Reactome and Biocarta. Molecular signatures
were considered to be significantly associated with treated
or untreated groups if they had a nominal P value of
<0001 and a false discovery score of <025. We acknowl-
edge our use of the gene set enrichment analysis, GSEA
software, and Molecular Signature Database (MSigDB).23
The raw data are available at https://www.repository.ca
m.ac.uk/handle/1810/254543
Statistical analysis
Differences between groups were tested using Student’s t-
test or non-parametric Mann–Whitney U-test as indi-
cated. Differences between animals regarding diabetes
incidence were tested using the Log rank survival test,
with P-values displayed within the relevant figure or
legend. Analysis was performed using GRAPHPAD PRISM soft-
ware (GraphPad Prism, San Diego, CA).
Results
Agly-anti-CD3 treatment prevents Th1-differentiated
pathogenic islet-specific CD4+ T cells from causing
disease but does not preferentially deplete them
Aglycosylated anti-CD3 antibody can activate mouse T
cells and cause cytokine production when used plate
bound in in vitro assays (see Supplementary material,
Fig. S1a), but soluble antibody fails to activate T cells in
co-culture with BMDC, confirming that it does not bind
Fc-receptors (see Supplementary material, Fig. S1b). As
the antibody cannot bind murine Fc-receptors it does not
cause release of large amounts of pro-inflammatory
cytokine, so avoiding an antibody-induced cytokine storm
(see Supplementary material, Fig. S1c). Intravenous injec-
tion of this antibody reversed diabetes in NOD mice
when injected at sufficiently high concentrations, whereas
a low concentration of 05 lg/dose given for five daily
doses did not have an effect on disease (see Supplemen-
tary material, Fig. S2). As shown previously with non-FcR
binding anti-CD3 antibodies, treatment with agly-anti-
CD3, but not isotype control antibody, decreased the
numbers of T cells but spared the Foxp3+ Treg popula-
tion (see Supplementary material, Fig. S3).
To investigate whether the observed preferential deple-
tion of non-Treg cells was caused by a selective depletion
of activated, pathogenic cells we used an adoptive transfer
system, where GFP+ labelled islet-specific Th1 differenti-
ated BDC2.5 CD4+ effector cells were transferred into 5-
week-old female NOD mice (Fig. 1a). These mice were at
least 5 weeks away from developing diabetes sponta-
neously, ensuring that the transferred Th1 cells could be
held responsible for rapid progression to diabetes. Treat-
ment with agly-anti-CD3 for 3 days prevented progres-
sion to diabetes, and prevented immune cell infiltration
into the islets (Fig. 1b,c). As the transferred effectors were
GFP+, we could seek these cells in spleen, pancreatic
lymph nodes and pancreas to assess if they had been pref-
erentially depleted by the treatment. Although the abso-
lute numbers of non-Treg cells had decreased in line with
previous results, the GFP+ CD4+/GFP CD4+ ratio
(Fig. 2a) was the same in both agly-anti-CD3 treated
mice and the isotype controls (Fig. 2b). This was the case
at any time-point we investigated after adoptive transfer
(Fig. 2c). We ascertained that the transferred effector cells
had not converted into FoxP3+ Treg cells, through use of
Th1 differentiated BDC2.5 cells from a donor mouse
expressing GFP under the Foxp3 promoter (see Supple-
mentary material, Fig. S4). In fact, it became obvious that
these cells, with potential to initiate disease, disappeared
quickly after adoptive transfer, and were all-but-gone
6 days after injection regardless of whether the recipient
mice received agly-anti-CD3 or isotype control treatment
(Fig. 2c).
Agly-anti-CD3 treatment down-regulates the
expression of genes involved in glycolysis and co-
stimulation and suppresses production of IFN-c in
pathogenic islet-specific T cells
To gain deeper understanding of how treatment with
agly-anti-CD3 affects the transferred Th1 cells to prevent
them from precipitating diabetes, we investigated changes
in their gene expression. We performed the same transfer
as described in Fig. 1(a), treating the recipient mice with
either agly-anti-CD3 or isotype control antibody, and
sorted the GFP+ cells from the pancreatic draining lymph
nodes 4 days following adoptive transfer. We then
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isolated RNA and performed microarray analyses to
detect any differences in gene expression between Th1
effector cells isolated from agly-anti-CD3-treated mice,
and those isolated from control mice (see Supplementary
material, Fig. S5). GSEA23 of microarray data of GFP+
transferred Th1 cells revealed several significantly different
molecular signatures in T cells from protected mice com-
pared with isotype-treated controls. Fourteen molecular
signatures were associated with untreated mice compared
with nine from anti-CD3-treated mice (see Supplemen-
tary material, Table S1). Of note, in comparison with
anti-CD3-treated cells, T cells from control ‘isotype’-trea-
ted mice had the transcriptional hallmark of activated
cells. These cells were enriched for glycolytic genes
(Fig. 3a) and components of the IL-6 and CD40 pathways
(Fig. 3b–d) including CD40 ligand, signal transducer and
activator of transcription 5, phosphoinositide 3 kinase
(PI3K) and mitogen-activated protein kinase.
In order to examine the effects of anti-CD3 treatment
on cell behaviour, we performed the same transfer and sort
as described previously (Fig. 1a), and re-stimulated the
cells for 4 hr with PMA and ionomycin. This analysis
revealed complete suppression of IFN-c production
(Fig. 4a) in the anti-CD3-treated group compared with the
isotype control. Studies in central nervous system inflam-
mation have suggested that anti-CD3 treatment may
induce IL-10 production in previously pathogenic cells,
and that this may be a mechanism for the protective effects
seen.24 However, in our experimental system we could find
no evidence that the potentially pathogenic transferred
GFP+ effector T cells had acquired IL-10 secretion (see
Supplementary material, Fig. S6). GLUT-1 is mostly main-
tained within the cell cytoplasm, to be transported to the
surface in response to activation. Analysis of surface
GLUT-1 revealed that GFP+ cells isolated from anti-CD3-
treated mice expressed lower levels of cell surface GLUT-1
(Fig. 4b), and lower levels of intracellular GLUT-1 (Fig.
4c), than their isotype-treated littermates. In addition,
GFP+ cells from the anti-CD3-treated group were smaller
(Fig. 4d). Both these observations indicate a less activated
status No difference in their mitochondrial content or their
production of superoxide (Fig. 4e) was discernible.
Agly-anti-CD3 inhibits T-cell-mediated activation of
antigen-presenting cells
The adoptively transferred cells disappeared quickly, and
6 days after transfer they were mostly undetectable
(Fig. 2c) even in the islet infiltrates, indicating that the
transferred cells had simply detonated the anti-islet pathol-
ogy and then disappeared. At 5 weeks of age there is nor-
mally only limited lymphocyte infiltration in the NOD
mouse islets, so it is clear that the transferred cells some-
how accelerated disease presumably by recruitment and
activation of host islet-reactive cells. One way this could
have happened is by the licensing of host dendritic cells,25–
27 a notion further supported by the changes in the CD40–
CD40 ligand pathway observed in the GSEA. We tested
this by investigating how pre-incubation with agly-anti-
CD3 affected the activation of mimotope-presenting
BMDC by Th1 differentiated BDC2.5 T cells in vitro. We
found that BMDC cultured with Th1 BDC2.5 pre-treated
with agly-anti-CD3 failed to up-regulate the co-stimulatory
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Figure 1. Agly anti-CD3 protects non-obese diabetic (NOD) mice
from developing diabetes after adoptive transfer of T helper type 1
(Th1) -differentiated BDC2.5 T cells. Adoptive transfer of GFP+
labelled Th1-differentiated BDC2.5 CD4+ T cells into 5-week-old
NOD female mice, followed by three daily injections of agly-anti-
CD3 (5 lg/day) (a) led to diabetes by day 5 in the isotype control
treated mice while agly-anti-CD3 treated mice remained healthy (b).
Histological examination of the pancreas is shown after treatment
with either agly-anti-CD3 (right) or control antibody (left), with
insulin stain in red (Alexa 546), CD4 in green (Alexa 488) and DAPI
in blue (c). The difference in diabetes incidence was tested using the
log-Rank survival test, (*P ≤ 005, **P ≤ 001, ***P ≤ 0001).
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molecule CD80 to the same extent as either positive con-
trols cultured without any antibody, or controls where the
BDC2.5 T cells had been pre-treated with the isotype anti-
body, which recognizes human CD3 (Fig. 5a). In addition,
the BMDC exposed to pre-treated Th1 differentiated
BDC2.5 T cells produced less IL-12 (Fig. 5b).
To investigate if treatment with agly-anti-CD3 affected
islet antigen presentation in vivo, we performed the same
transfer as described in Fig. 1(a), and then either tested
the capacity of pancreatic lymph node-derived antigen-
presenting cells to present endogenous antigen to naive
BDC2.5 CD4 T cells ex vivo (Fig. 5c) or completely
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Figure 2. Agly anti-CD3 does not cause prefer-
ential depletion of transferred pathogenic cells.
The gating strategy for the analysis of the per-
centage of known pathogenic
GFP+ CD4+ 7AAD B220 is shown in (a),
and the percentage of GFP+ T cells within the
CD4+ T-cell compartment in the indicated
organs at 4 days after adoptive transfer (b).
The percentage of GFP+ T cells within the
CD4+ T-cell compartment in inguinal lymph
nodes, spleen, pancreatic lymph nodes and
pancreas at various time-points after adoptive
transfer is indicated in (c). Each data point in
(b) represents one mouse, and the experiment
was performed at least twice for each time-
point. The data points in (c) represent an aver-
age of at least five mice. Differences between
groups were tested using Student’s t-test.
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in vivo through injection of the naive CFSE-labelled
BDC2.5 cells 3 days after the last antibody injection
(Fig. 5d). We found that BDC2.5 CD4+ T-cell prolifera-
tion was modestly but significantly decreased in agly-anti-
CD3-treated pancreatic lymph nodes both when assessed
ex vivo (Fig. 5c) and in vivo (Fig. 5d).
Agly-anti-CD3 increases expression of PD-1 on
pathogenic islet-specific T cells
Expression of PD-L1 on antigen-presenting cells is an
important regulator of anti-islet immune responses,13,28–31
and blockade of this interaction can precipitate diabetes in
prone strains.29,32 Furthermore, blockade of PD-1/PD-L1
increases the interaction time between T cells and antigen-
presenting cells, so indirectly enhancing activation.33 We
used the same experimental set up described in Fig. 1(a),
and found that anti-CD3 treatment leads to around an
eight-fold increase in the expression of PD-1 on the GFP+
donor-derived formed Th1 cells (Fig. 6a). Anti-PD-L1-
accelerated diabetes in wild-type NOD mice could be
delayed by anti-CD3 treatment, but this protective effect
was lost if anti-CD3 therapy was discontinued while PD-
L1 antibody remained in the system (Fig. 6b), the half-life
of anti-PD-L1 antibody being c. 7 days.34 Only anti-CD3
treatment that continued beyond the point when anti-PD-
L1 was sufficiently purged from the system was sufficient
to establish lasting tolerance and euglycaemia (Fig. 6c).
Discussion
Anti-CD3 treatment has shown efficacy in certain clinical
trials, with prolongation of time to dependence on exoge-
nous insulin administration in treated patients, and lower
levels of HbA1c. The fact that anti-CD3 treatment in
humans failed to mimic the complete remission seen in
diabetic mice initially disappointed the type 1 diabetes
community. However, detailed analysis of the treated
cohorts indicates that success might be increased through
focus on particular subgroups such as younger patients7 or
in patients identifiable by lower HbA1c and insulin
requirement at the beginning of the study.6,35 It is also
clear that too low an antibody dose fails to achieve any
positive effects,36 which, as we demonstrate in this paper,
is also true in NOD mice. There is a growing consensus to
consider combination therapies targeting different aspects
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Figure 3. Gene set enrichment analysis of microarray data from donor T helper type 1 (Th1) cells after treatment with either isotype antibody or
agly-anti-CD3. wild-type non-obese diabetic (Wt NOD) female mice received 5 9 105 Th1 differentiated BDC2.5 CD4+ T cells, and were then
treated with isotype control antibody or agly-anti-CD3 as described in Fig. 1. Four days after transfer, the GFP+ cells were sorted from the pan-
creatic lymph nodes of the mice, and the sorted cells were prepared for microarray analysis. Each agly-anti-CD3 sample was pooled from three
or four mice, and each control sample was pooled from two or three mice. Molecular signature data sets analysed included hallmark data sets (a)
and curated gene sets (b-d). Glycolysis genes are enriched in untreated T cells (a), the leading edge set of genes, those contributing most to the
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of disease, such as inflammation and beta cell function, in
order to improve outcome,37 and that anti-CD3 treatment
could be a useful component in such an approach.37–39
Previous work has described a preferential depletion of
Th1 differentiated cells after anti-CD3 treatment.11,14 In
this study we wanted to determine in detail which
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Figure 4. Functional studies of T helper type 1 (Th1) cells after treatment with either isotype control antibody or agly-anti-CD3. Wild-type non-
obese diabetic (wt NOD) female mice received 5 9 105 Th1 differentiated BDC2.5 CD4+ T cells, and were then treated with isotype control anti-
body or agly-anti-CD3 as described in Fig. 1. Four days after transfer the GFP+ cells were sorted from the pancreatic lymph nodes of the mice.
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except in (a), where each data point is a pool of two or three mice. Each experiment was repeated at least twice. Differences between groups were
tested using Student’s t-test.
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‘activated’ cells disappear through use of GFP-labelled
Th1-differentiated islet-specific BDC2.5 CD4+ T cells,
injected into young, pre-diabetic female NOD mice. In
this case, we know that the peptide recognized by the
BDC2.5 cells is presented in the pancreatic lymph
nodes,16 and that these cells cause rapid progression to
diabetes after transfer.40 Interferon-c is necessary for
CD4+ T-cell-mediated beta cell destruction, as demon-
strated by studies blocking the cytokine41 as well as
studies in mice without a functional receptor.42 We found
that the transferred cells disappeared quickly after trans-
fer, and were mostly gone around 6 days after injection
when disease became apparent. The massive infiltrates
around the pancreatic islets consisted almost entirely of
endogenous T cells and recruited mononuclear cells. It
appears therefore, that the transferred activated cells pre-
cipitated disease, but did so within a very short time win-
dow of activation. The composition of the CD4+ T-cell
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Figure 5. Agly-anti-CD3 inhibits T cells from activating antigen-presenting cells (APC). Pre-incubation with agly-anti-CD3 prevents T helper
type 1 (Th1) differentiated BDC2.5 T cell from activating bone marrow-derived dendritic cells (BMDC). Levels of co-stimulatory molecule CD80
on the co-cultured BMDC (a) were measured by flow cytometry, and interleukin-12 (IL-12) in the culture medium was detected by ELISA (b).
Controls are BMDC cultured alone, positive control cultures have Th1 cells added without pre-incubation with antibody, and in hCD3 cultures
the Th1 cells have been pre-incubated with the isotype control antibody which binds human, but not mouse CD3. Mice were injected and treated
as in Fig. 1, and pancreatic nodes used as antigen-presenting cells to CFSE-labelled BDC25 CD4+ cells in vitro (c) or in vivo (d) to assess prolif-
eration. Differences between groups were determined using the non-parametric Mann-Whitney test (*P ≤ 005, **P ≤ 001, ***P ≤ 0001). The
results are representative of at least three experiments.
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population at different time-points after transfer showed
that anti-CD3 treatment, albeit completely protecting
mice from developing diabetes, did not preferentially
deplete the originally transferred GFP+ cells, as these were
present in equal ratios in both anti-CD3-treated and con-
trol-treated mice, but rather prevented further activation
of subsequent waves of islet-reactive T cells.
Investigation of peripheral blood mononuclear cells in
teplizumab recipients has identified differential expression
of several genes involved in T-cell activation and effector
function.43 In our experiments, GSEA of microarray data
of GFP+ transferred Th1 cells showed some major differ-
ences between treated and untreated cells. Fourteen
molecular signatures were strongly associated with cells
from untreated mice, compared with nine from anti-
CD3-treated mice. T cells from isotype-treated control
mice had the transcriptional hallmark of activated cells.
The finding that untreated effector Th1 cells were strongly
enriched in transcripts encoding components of the gly-
colysis pathway suggests that anti-CD3 treatment may in
some way suppress metabolic activity or alternatively
select or skew T cells to other modes of metabolism such
as fatty acid metabolism. This shift in metabolic mode
has been well described in Treg cells and memory T
cells.44,45 A recent report described that signalling though
PD-1 leads to down-regulation of glycolysis in T cells,46
and in our studies we find that PD-1 is up-regulated in
the anti-CD3-treated effector cells. Previous studies have
demonstrated that blockade of PD-1/PD-L1 interaction
increases the interaction time between T cells and anti-
gen-presenting cells and enhances activation,33,47 and
expression of PD-L1 is important for regulating anti-islet
immune responses.28–32 Our results show that anti-CD3
treatment up-regulates PD-1 on effector T cells, and that
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Figure 6. Agly anti-CD3 treatment increases programmed death 1 (PD-1) expression on islet-specific effector T cells, and blockade of PD-1 acti-
vation overcomes agly anti-CD3-induced protection from diabetes. Wild-type non-obese diabetic (Wt NOD) female mice received 5 9 x105 T
helper type 1 (Th1) differentiated BDC2.5 CD4+ GFP+ T cells, and were then treated with isotype control antibody or agly-anti-CD3 as described
in Fig. 1. Four days after transfer the cells in the pancreatic lymph nodes were assessed for PD-1 expression (a). Injection of 2 mg of anti-PD-L1
antibody in pre-diabetic NOD mice combined with short term (5 injections) (b) or longer (10 injections) (c) treatment with agly-anti-CD3
(5 lg/day). Differences between groups in (b) and (c) were assessed using the Log Rank survival test (*P ≤ 005, **P ≤ 001, ***P ≤ 0001).
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anti-CD3 treatment is not effective if the PD-1/PD-L1
pathway is inhibited. In our studies of PD-L1 blockade,
both activated islet-specific cells as well as naive cells are
potentially affected by the anti-PD-LI, and it remains to
be determined if the increase of PD-1 is the most impor-
tant factor in the anti-CD3-mediated reduction of
pathogenicity. It will be interesting to assess further the
effects of anti-CD3 on Th1 cellular metabolism, and
whether up-regulation of PD-1 precedes the decrease in
glycolytic activity. It is also notable that treatment down-
regulated pathways involved in co-stimulation of antigen-
presenting cells, as well as the PI3K signalling pathway,
which is of crucial importance for IFN-c secretion.48,49
The GSEA data support the notion that ex-Th1 cells have
been reprogrammed to become less activated or pro-
inflammatory. This could be due, at least in part, to the
increased ratio of Foxp3+ Treg cells present11,50 and ele-
vated levels of transforming growth factor-b (TGF-b) in
treated recipients,13,51,52 as well as to direct effects medi-
ated by the antibody treatment of the effector cell itself.
To further investigate this, we investigated the functional
properties of the cells from treated animals. We discov-
ered that these ex-Th1 cells were now inhibited from
secreting the Th1 hallmark cytokine IFN-c, which is nec-
essary for islet-specific CD4+ T cells to cause diabetes,40,42
indicating that treatment had completely changed their
behaviour.
The down-regulation of the CD40 pathway suggested by
the microarray data indicated that effector cells from trea-
ted mice may be deficient in their capacity to licence DC,
and so be prevented from perpetuating the anti-islet
immune response. In addition, the lack of IFN-c in anti-
CD3-treated ex-Th1 cells would impact on their capacity
to licence antigen-presenting cells, as has been demon-
strated in studies of CTLA4-immunoglobulin-induced tol-
erance.27 We found that pre-incubation with agly-anti-
CD3 prevented Th1 differentiated BDC2.5 CD4+ T cells
from activating BMDC in co-culture, both as measured by
up-regulation of the co-stimulatory molecule CD80, and
secretion of IL-12, which is important to their activating
function. We previously found that DC that are unable to
deliver full activation signals may, by default, induce toler-
ance, T-cell unresponsiveness, and Treg cells.53 Foxp3+
Treg cells themselves can also inhibit DC function,54 an
effect that can be broken by additional CD40 ligand stim-
ulation.55 Administration of tolerogenic DC potentiates
the protective effects of anti-CD3 in allogeneic islet trans-
plantation.56 Antigen presentation is influenced by the
actions of TGF-b,57,58 the production of which is of cru-
cial importance for the protective effect of anti-CD3 treat-
ment13,51 and which can be further amplified through
uptake of apoptotic T cells by macrophages.59
An interesting aspect of anti-CD3-mediated protection
from type 1 diabetes in mice is the importance of timing.
Contrary to many other treatment regimens, anti-CD3
treatment is only effective if administered once the mice
have become diabetic, and not before.60 The effects of
anti-CD3 treatment on tolerance to transplanted tissue is
also highly dependent on the timing of administration,
with treatment coinciding with the priming of alloreactive
immune responses (3–7 days after transplant), affording
long-term graft survival, which earlier treatment (day 1–3)
could not.14,50 This may reflect the need for a sufficiently
high number of activated islet-reactive T cells to be tar-
geted by anti-CD3 therapy to enable some of the longer-
term manifestations necessary for tolerance. The rapid
turnover of pathogenic cells seen in our study supports
the concept of a crucial treatment window, as the period
during which they exert their effect to achieve a perpetua-
tion of the anti-islet immune response is so brief.
In this report we describe how a mouse equivalent of
otelixizumab, agly-anti-CD3, prevents pathogenic islet-
specific Th1 cells from causing diabetes by inhibiting their
metabolism, CD40 signalling and cytokine production,
and through up-regulating PD-1 expression. Anti-CD3
does not preferentially deplete these cells, but prevents
them from being pathogenic and from contributing to
activation of naive cells. Inhibition of PD-1/PD-L1 inter-
action breaks the protective effect of anti-CD3 treatment
in wild-type NOD mice. We propose that inhibition of
effector T-cell metabolism and function, and the down-
stream consequences of this, operates in combination
with the favourable ratio of Foxp3+ Treg cells and ele-
vated levels of TGF-b to provide the long-term protective
effect of the short treatment with aglycosyl-anti-CD3 anti-
body.
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online version of this article:
Figure S1. Properties of agly-anti-CD3.
Figure S2. Injection of agly-anti-CD3 reverses diabetes
in non-obese diabetic mice in a dose-dependent manner.
Figure S3. Agly-anti-CD3 treatment increases the per-
centage of Foxp3+ regulatory T (T reg) cells through
selectively sparing this population.
Figure S4. Treatment with agly-anti-CD3 does not
cause conversion of islet specific T helper type 1 (Th1)
effector cells to Foxp3+ regulatory T (Treg) cells.
Figure S5. Heatmap presentation of microarray data
comparing islet specific T helper type 1 (Th1 cells from
agly-anti-CD3 treated and isotype-treated mice.
Figure S6. T helper type 1 (Th1) differentiated cells
from agly-anti-CD3-treated recipients do not produce
interleukin-10 (IL-10) when restimulated.
Table S1. All the significantly enriched molecular sig-
natures associated with anti-CD3 treated or untreated
cells are listed.
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